6:22 AM
 | 
Jun 29, 2018
 |  BioCentury  |  Finance

Nailing down NLRP3

Why investors backed $37M series A for inflammasome play NodThera

The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures.

F-Prime Capital Partners and founding investor Epidarex Capital also joined the round, which was announced on June 25.

First-generation NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1) inhibitors originated more than a decade ago but were never brought to the clinic. Acting NodThera CEO Alan Watt told...

Read the full 369 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >